DF Dent & Co. Inc. Has $40.13 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

DF Dent & Co. Inc. trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 542,137 shares of the medical research company’s stock after selling 1,736 shares during the period. DF Dent & Co. Inc. owned 0.09% of Edwards Lifesciences worth $40,134,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in EW. Wellington Management Group LLP grew its position in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. Norges Bank acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $610,895,000. Jennison Associates LLC bought a new position in Edwards Lifesciences during the 4th quarter worth $555,939,000. Vanguard Group Inc. raised its holdings in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after acquiring an additional 3,506,886 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Price Performance

Shares of EW opened at $72.09 on Thursday. The business has a 50-day moving average of $71.65 and a 200-day moving average of $70.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $42.38 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,553 shares of company stock worth $4,513,064 over the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.